Modeling dose rate increase from the addition of Uranium-232 for use as a tracer in uranium fuels.

Appl Radiat Isot

University of Tennessee, Nuclear Engineering, 863 Neyland Drive, Knoxville, TN, 37996, USA. Electronic address:

Published: October 2022

The isotope U is being considered for additive to uranium fuel for use as a tracer. The U decay chain has high energy gammas that can be used for tracer purposes. However, the presence and intensity of such gammas may increase effective dose rates to workers around such materials This study examines the dose rate from different uranium materials that varying amounts of U has been added to. Several materials and their respective storage geometries are modeled for particle transport calculations. For each material and U concentration, gamma source terms were generated using SCALE 6.2 ORIGEN. These source terms were then used in MCNP for each material and geometry. Upon analysis, it was determined that the baseline dose from enriched uranium dominates until the U concentration reaches about 10-100 parts per trillion (ppt), after which the dose rate increases linearly.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.apradiso.2022.110385DOI Listing

Publication Analysis

Top Keywords

dose rate
12
source terms
8
modeling dose
4
rate increase
4
increase addition
4
addition uranium-232
4
uranium-232 tracer
4
uranium
4
tracer uranium
4
uranium fuels
4

Similar Publications

Importance: Retrieval strategies for children, adolescents, and young adults with relapsed classic Hodgkin lymphoma (cHL) aim to maintain efficacy while minimizing long-term toxic effects. Children, adolescents, and young adults with low-risk, relapsed cHL may benefit from replacing high-dose chemotherapy and autologous stem cell transplant with less intensive involved-site radiotherapy (ISRT).

Objective: To evaluate a risk-stratified, response-adapted, transplant-free approach for treatment of children, adolescents, and young adults with low-risk relapsed cHL with nivolumab plus brentuximab vedotin (BV) followed by BV plus bendamustine for patients with suboptimal response and ISRT (30.

View Article and Find Full Text PDF

Background: Radiation segmentectomy (RS) is an alternative potential local curative treatment for selected colorectal liver metastases (CLMs) not amenable to ablation or limited resection.

Purpose: The aim of this study was to evaluate the dosimetric response of low volume CLMs to RS in heavily pretreated patients who are not candidates for resection or percutaneous ablation.

Patients And Methods: This single-center retrospective study evaluated CLMs patients treated with RS (prescribed tumor dose >190 Gy) from 2015 to 2023.

View Article and Find Full Text PDF

Purpose: Activating T cell costimulatory receptors is a promising approach for cancer immunotherapy. In preclinical work, adding an OX40 agonist to in situ vaccination (ISV) with SD101, a TLR9 agonist, was curative in a mouse model of lymphoma. We sought to test this combination in a Phase I clinical trial for patients with low-grade B cell lymphoma.

View Article and Find Full Text PDF

This study investigated the effects of on alleviating loperamide-induced constipation. To evaluate the efficacy of in Sprague-Dawley (SD) rats, fecal parameters, the intestinal transit rate, and changes in intestinal mucosal cells were measured through histological analysis. Additionally, serotonin levels, water absorption, tight junction-related gene expression, and the cecal short-chain fatty acid (SCFA) content were analyzed.

View Article and Find Full Text PDF

We investigate the evidence for adverse effects of intraparenchymal and peritumoral application of isosulfan blue dye in sentinel lymph node (SLN) mapping in breast cancer patients. A meta-analysis on the adverse effects of intraparenchymal and peritumoral application of isosulfan application in SLN mapping was conducted using Medline and Embase databases up to 2023. Procedure-based adverse reactions were divided into three grades: Grade I (allergic skin reactions), Grade II (hypotension) and Grade III (requiring vasopressor support).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!